Targeted therapy for triple-negative breast cancer: Where are we?

International Journal of Cancer

Volumn 131, Issue 11, 2012, Pages 2471-2477

  Duffy, Michael J ^a,b   McGowan, Patricia M ^b   Crown, John ^a,c  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

biomarkers; PARP; predictive markers; triple negative breast cancer

Indexed keywords

AGO 14699; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DASATINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; ETOPOSIDE; GEFITINIB; GEMCITABINE; INIPARIB; IRINOTECAN; K RAS PROTEIN; LAPATINIB; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PANITUMUMAB; PLATINUM COMPLEX; PROGESTERONE RECEPTOR; PROTEIN KINASE P60; SCATTER FACTOR RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIARRHEA; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DYSPNEA; EGFR GENE; FATIGUE; GENE; GENE OVEREXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; ONCOGENE K RAS; PHARMACOGENETICS; PLEURA DISEASE; PRIORITY JOURNAL; PTEN GENE; REVIEW; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84867072867     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27632     Document Type: Review

References (90)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
2. Sorlie T, Perou CM, Tibshiranie R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74.
3. Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009; 15: 907-13.
4. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to- mesenchymal transition and stem cell characteristics. Cancer Res 2009; 69: 4116-24.
5. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
6. Foulkes WD, Smith IE, Reis-Filho JS,. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-48.
7. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121. p ii: 45014. doi: 10.1172/JCI45014.
8. Carey L,. Directed therapy of subtypes of triple negative breast cancer. Oncologist 2010; 15 (Suppl 3): 8-15.
9. Browne BC, O'Brien N, Duffy MJ, et al. HER-2 signaling and inhibition in breast cancer. Curr Cancer Drug Therapy 2009; 9: 419-38.
10. Duffy MJ, O'Donovan N, Crown J,. Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 2011; 37: 151-9.
11. Hoadley KA, Weigman VJ, Fan C, et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genom 2007; 8: 258.
12. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-74.
13. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
14. Ryden L, Jirstrom K, Haglund M, et al. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat 2010; 120: 491-8.
15. Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009; 15: 2302-10.
16. Viale G, Rotmensz N, Maisonneuve P, et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009; 116: 317-28.
17. Hochgräfe F, Zhang L, O'Toole SA, et al. Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. Cancer Res 2010; 70: 9391-401.
18. Heiser LM, Sadanandam A, Kuo WL, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci USA 2012; 109: 2724-29.
19. Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009; 20: 862-7.
20. O'Shaughnessy J, Weckstein DJ, Vukelja SJ, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007;106;Abstract 308.
21. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 2008; 26 (Suppl 15):abstract 1009.
22. Baselga J, Gomez P, Awada A, et al. The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized phase II study (BALI-1). Ann Oncol 2010; 21 (Suppl 8): viii96.
23. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-10.
24. Shankaran V, Obel J, Benson AB, III,. Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. Oncologist 2010; 15: 157-167.
25. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 2004; 19: 208-12.
26. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238-47.
27. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97: 1139-45.
28. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27: 2622-9.
29. Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009; 69: 3256-61.
30. Saal LH, Gruvberger-Saal SK, Persson C, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008; 40: 102-7.
31. Andre F, Job B, Dessen P, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009; 15: 441-51.
32. Astsaturov I, Ratushny V, Sukhanova A, et al. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal 2010; 3: ra67.
33. Dong Y, Li A, Wang J, et al. Synthetic lethality through combined notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res 2010; 70: 5465-74.
34. Liu T, Yacoub R, Taliaferro-Smith LD, et al. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells. Mol Cancer Ther 2011; 10: 1460-9.
35. Liu X, Newton RC, Scherle PA,. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 2010; 16: 37-45.
36. Ponzo MG, Lesurf R, Petkiewicz S, et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA 2009; 106: 12903-8.
37. Graveel CR, DeGroot JD, Su Y, et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci USA 2009; 106: 12909-14.
38. Charafe-Jauffret E, Ginestier C, Monville F, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006; 25: 2273-84.
39. Gastaldi S, Comoglio PM, Trusolino L,. The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res 2010; 12: 208.
40. Cecchi F, Rabe DC, Bottaro DP,. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 2010; 46: 1260-1270.
41. Canadas I, Rojo F, Arumi-Uria M, et al. C-MET as a new therapeutic target for the development of novel anticancer drugs. Clin Transl Oncol 2010; 12: 253-60.
42. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-703. Erratum in: N Engl J Med 2011;364:588.
43. Grande E, Bolós MV, Arriola E,. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther 2011; 10: 569-79.
44. Montero JC, Seoane S, Ocaña A, et al. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 2011; 17: 5546-52.
45. Kim LC, Song L, Haura EB,. Src kinase as a therapeutic target for cancer. Nat Rev Clin Oncol 2009; 6: 587-95.
46. Tryfonopoulos D, Walsh S, Collins D, et al. Src: A potential target for the treatment of triple-negative breast cancer. Ann Oncol 2011; 22: 2234-40.
47. McCormack PL, Keam SJ,. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs 2011; 71: 1771-95.
48. Breccia M,. Hematology: Nilotinib and dasatinib-new 'magic bullets' for CML? Nat Rev Clin Oncol 2010; 7: 557-8.
49. Finn S, Dering, J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319-26.
50. Kurebayashi J, Kanomata N, Moriya T, et al. Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype. BMC Cancer 2010; 10: 568.
51. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumours to dasatinib: rationale for patient selection. Cancer Res 2007; 6; 2226-38.
52. Pichot CS, Hartig SM, Xia L, et al. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 2009; 101: 38-47.
53. Ceppi P, Papotti M, Monica V, et al. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin. Mol Cancer Ther 2009; 8: 3066-77.
54. Serrels A, Macpherson IR, Evans TR, et al. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 2006; 5: 3014-22.
55. Moulder S, Yan K, Huang F, et al. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther 2010; 9: 1120-7.
56. Finn RS, Bengala C, Ibrahim N, et al. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 2011; 17: 6905-13.
57. Mayer EL, Krop IE,. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 2010; 16: 3526-32.
58. Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10: 293-301.
59. Rowe BP, Glazer PM,. Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. Breast Cancer Res 2010; 12: 203.
60. Amir E, Seruga B, Serrano R, et al. Targeting DNA repair in breast cancer: a clinical and translational update. Cancer Treat Rev 2010; 36: 557-65.
61. Ashworth A,. Drug resistance caused by reversion mutation. Cancer Res 2008; 68: 10021-3. Review.
62. Banerjee S, Kaye SB, Ashworth A,. Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol 2010; 7: 508-19.
63. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
64. Bryant HE, Schultz N, Thomas HD,. Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-7.
65. Drew Y, Mulligan EA, Vong W-T, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 2011; 103: 1-13.
66. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34.
67. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-44.
68. Anders CK, Winer EP, Ford JM, et al. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res 2010; 16: 4702-10.
69. Annunziata CM, O'Shaughnessy J,. Poly(adp-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res 2010; 16: 4517-26.
70. Hastak K, Alli E, Ford JM,. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 2010; 70: 7970-80.
71. O'Shaughnessy J, Osborne C, Pippen JE, et al. Inaparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 204-14.
72. O'Shaughnessy JS, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011; 15 - Suppl (May 20 Supplement): 107.
73. Liu X, Shi Y, Maag DX, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012; 18: 510-23.
74. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12: 852-61.
75. Moskwa P, Buffa FM, Pan Y, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 2011; 41: 210-20.
76. Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1: 315-22.
77. McEllin B, Camacho CV, Mukherjee B, et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 2010; 70: 5457-64.
78. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010; 2: 53ra75.
79. Mukhopadhyay A, Elattar A, Cerbinskaite A, et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 2010; 16: 2344-51.
80. Wang LH, Pfister TD, Parchment RE, et al. Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res 2010; 16: 1073-84.
81. Redon CE, Nakamura AJ, Zhang YW, et al. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 2010; 16: 4532-42.
82. Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Clin Cancer Res 2009; 69: 565-72.
83. Lee CW, Simin K, Liu Q, et al. A functional notch-survivin gene signature in basal breast cancer. Breast Cancer Res 2008; 10: R97.
84. McGowan P, Mullooly M, Sukor S, et al. ADAMs as new therapeutic targets for triple negative breast cancer. J Clin Oncol 2011; 29 (Suppl; abstr 1062).
85. McGowan P, Mullooly M, Sukor S, et al. ADAM17 a novel therapeutic target for treatment of triple negative breast cancer? Cancer Res 2011; 71 (24 Suppl); 416s.
86. Sharpe R, Pearson A, Herrera-Abreu MT, et al. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 2011; 17: 5275-86.
87. Turner N, Lambros MB, Horlings HM, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29: 2013-23.
88. Litzenburger BC, Creighton CJ, Tsimelzon A, et al. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res 2011; 17: 2314-27.
89. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299-309.
90. Hoeflich KP, O'Brien C, Boyd Z, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009; 15: 4649-64.